Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb;4(3):51.
doi: 10.3978/j.issn.2305-5839.2015.10.44.

Immunological interactions in radiotherapy-opening a new window of opportunity

Tapesh Bhattacharyya  1 , Kiran Purushothaman  1 , Sanudev Sadanandan Vadakke Puthiyottil  1 , Atanu Bhattacharjee  1 , Geetha Muttah  1
Affiliations
Review

Immunological interactions in radiotherapy-opening a new window of opportunity

Tapesh Bhattacharyya et al. Ann Transl Med. 2016 Feb.

Abstract

After a span of significant developments & advances we have reached a plateau in all the oncological disciplines in last decade. Escalation of dose of radiotherapy (RT) became possible with emergence of intensity modulated radiotherapy (IMRT) and image guided radiotherapy (IGRT). Different radiosensitizing agents starting from conventional cytotoxic drugs to hypoxic radiosensitizers have been tried to increase the effect of RT. However technological advancement hasn't been translated into significant clinical benefits. Exploiting the immune system to enhance the effect of RT is a relatively new concept and a fast growing area in the field of oncology. RT cannot longer be considered as a localized treatment, but rather as a systemic weapon for solid tumors. The phenomenon of abscopal effect, meaning the action of RT upon distant 'out-of-field' foci of malignancies has been a major focus of recent research, and holds great promise for the future. In this review article we are going to discuss the immunological interactions in RT and its promising clinical implications.

Keywords: Immunology; PD-L1; cytotoxic T lymphocyte antigen-4 (CTLA-4); radiotherapy (RT).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Radiotherapy and its role in cancer immune cycle. CTLA-4, cytotoxic T lymphocyte antigen-4.
See this image and copyright information in PMC

References

    1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. - PubMed
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74. - PubMed
    1. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:11-22. - PubMed
    1. Delves PJ, Martin SJ, Burton DR, et al. Roitt's Essential Immunology. 12th edition. New York: Wiley Blackwell, 2011.
    1. Comber JD, Philip R. MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines. Ther Adv Vaccines 2014;2:77-89. - PMC - PubMed